In reply
I appreciate the letter by Whittle calling attention to the fact that I did not list any conflicts of interest in my invited commentary concerning the use of β-adrenergic receptor blocking agents in patients with heart failure.1 I have been careful to list all of my potential conflicts of interest in the articles I publish and review including the articles I reviewed concerning the use of β-adrenergic receptor blockers in patients with heart failure, which were the subject of my commentary.2-3 I regret not having restated these conflicts in the submission of my commentary. I realize the importance of transparency, especially in view of the many recent disclosures of apparent conflicts of interest.
Although I have not consulted or been involved in any study of β-adrenergic receptor blockers for the last several years, some of the pharmaceutical companies I consult for on other projects have . . . [Full Text of this Article]
AUTHOR INFORMATION
